Identification of high-risk patients with a seven-biomarker prognostic signature for adjuvant treatment trial recruitment in American Joint Committee on Cancer v8 stage I-IIA cutaneous melanoma.

Stefanie Meyer,Lorenz Buser,Sebastian Haferkamp,Mark Berneburg,Tim Maisch,Monika Klinkhammer-Schalke,Armin Pauer,Thomas Vogt,Claus Garbe

European journal of cancer (Oxford, England : 1990)（2023）

引用 2|浏览10

暂无评分

摘要

In patients with AJCC early-stage disease, the 7-marker signature reliably prognosticates melanoma-related outcomes, independent of AJCC classification, and provides a valuable complement to clinicopathological/demographic factors.

查看译文

关键词

Data collection,Disease-free survival (DFS),Malignant melanoma,Prognostic factor,Prospective studies,Risk assessment,Survival,Tumour staging

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要